Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Grifols SA GRFS

Healthcare Drug Manufacturers - Major
Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma, and severe burns; alpha-1 proteinase inhibitor, a plasma protein,... see more

Current News (NDAQ:GRFS)

Grifols Pioneers High-Tech Analysis of Plasma Bank to Detect Early Signs of Parkinson's Disease

GlobeNewswire January 14, 2025

Grifols Receives FDA Approval to Treat Surgical Bleeding in Pediatric Patients With its Fibrin Sealant Solution

GlobeNewswire October 29, 2024

Grifols Partners with BARDA for Proof-of-Concept Testing of Ocular Immunoglobulin as Treatment for Sulfur Mustard-Induced Eye Injury

GlobeNewswire October 22, 2024

The Schall Law Firm Is Looking Into Grifols SA For Possible Securities Related Improprieties And Stockholders Are Invited To Reach Out

ACCESS Newswire September 6, 2024

Grifols S.A. May Have Committed Fraud And Investors Are Urged To Contact The Schall Law Firm About An Inquiry

ACCESS Newswire September 5, 2024

Grifols SA May Have Committed Securities Fraud And Investors With Losses Should Join The Schall Law Firm's Inquiry

ACCESS Newswire September 3, 2024

An Investigation Has Been Launched By The Schall Law Firm Into Grifols S.A.'s Possible Securities Law Violations And Shareholders Can Join

ACCESS Newswire September 2, 2024

Grifols SA Is Being Looked Into For Securities Fraud And Investors Should Reach Out To The Schall Law Firm About The Inquiry

ACCESS Newswire September 1, 2024

The Schall Law Firm Wants The Public To Participate In An Investigation Into Grifols S.A.'s Possible Securities Law Violations

ACCESS Newswire August 31, 2024
View More News ››

Opinion & Analysis (NDAQ:GRFS)

Stellar Biotechnologies (SBOT:NASDAQ) could rise with KLH vaccine trial success

The Life Sciences Report March 2, 2017
View More Opinion ››

Bullboard Posts (NDAQ:GRFS)

$GRFS Declines Amid Buyout Rejection, $MYNZ Shines

$GRFS dropped on Nov 27 as the board declined Brookfield’s €6.45B buyout offer, citing its undervaluation. The €10.50 per Class A bid...
Trader19Swift - November 27, 2024
View more Bullboard ››

Boron One Holdings Inc.

Boron One Holdings Inc.

Boron One Holdings Inc. engages in the acquisition, exploration, and development of mineral properties in Serbia. The company ...
View More »

Podcasts